Lumpectomy Yields Clinically ‘Acceptably Low’ Recurrence Rates in Breast Cancer Subtype

Video

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota details the efficacy of breast-conserving surgery in patients with multiple ipsilateral breast cancer.

Patients with multiple ipsilateral breast cancer should now be able to consider breast conservation therapy as a suitable treatment option along with mastectomy following clinically acceptable local recurrence rate, according to Judy C. Boughey, MD.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Boughey, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery at Mayo Clinic in Rochester, Minnesota, about efficacy findings for breast conservation therapy in patients with multiple ipsilateral breast cancer from the phase 2 ACOSOG Z11102 (Alliance) trial (NCT01556243).

According to Boughey’s presentation on the trial, 6 of 204 patients had developed local recurrence following surgery with an estimated cumulative incidence of local recurrence after 5 years of 3.1% (95% CI, 1.3%-6.4%). These data fulfilled the trial’s prespecified acceptable 5-year recurrence rate of less than 8%.

Transcript:

In this prospective clinical trial, we enrolled over 200 women with 2 or 3 foci of breast cancer. They were then treated with breast conserving surgery [with] lumpectomy, [thus] preserving the breast, followed [by] whole breast radiation therapy along with radiation to all of the lumpectomy sites.

In this trial, we set the boundary to be that the local recurrence rate could not be any higher than 8% with a 5-year follow-up. We [reported] the 5-year follow-up on the Alliance Z11102 clinical trial, which showed that in these patients who completed breast conserving therapy—so surgery and radiation therapy—the local recurrence rate at 5 years was 3.1%.

This is an acceptably low local recurrence rate, which is clinically acceptable. [Based on that], patients who have multiple ipsilateral breast cancer can now consider their treatment options to be either mastectomy or breast-conserving therapy.

Reference

Boughey JC, Rosenkranz KM, Ballman KV, et al. Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – results from ACOSOG Z11102 (Alliance). Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX; abstract GS4-01.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content